Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
NCT01417000
Completed
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to GVAX pancreas vaccine (with cyclophosphamide) alone in adults who have failed or refused prior treatment for metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2018
Locations: H. Lee Moffitt Cancer Center, Tampa, Florida +9 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
NCT00794820
Completed
Primary Objective: * To evaluate the efficacy (combined morphologic and flow remissions) of a combination of fludarabine, cyclophosphamide and multiple dose rituximab as frontline therapy for CLL. Secondary Objective: * To evaluate remission duration and survival.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/05/2018
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia
Register for Updates
A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer
NCT00001426
Completed
A supra-additive cytotoxic effect was seen when CAI and paclitaxel were given to human ovarian cancer cells sequentially in tissue culture. We have demonstrated that CAI given for 8 days followed by paclitaxel is reasonably well tolerated and that paclitaxel administration causes a dose-dependent increase in CAI plasma concentration. CAI is a cytostatic drug and continuous exposure is needed. This study will evaluate the combination of continuously administered CAI with three-weekly paclitaxel.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/04/2018
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Ovarian Neoplasm
Register for Updates
Carbohydrate-Protein Supplementation During Endurance Running
NCT00972387
Completed
The purpose of this study is to assess whether the greater performance benefits from ingesting carbohydrate-protein supplements during endurance running, in comparison to the traditionally used carbohydrate supplement, is attributed to the extra calories contained in the carbohydrate-protein supplement or the presence of protein.
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
04/03/2018
Locations: Health Physical Education and Recreation Building, Knoxville, Tennessee
Conditions: Supplementation During Endurance Performance
Register for Updates
Fasting on Newly Diagnosed Breast Cancer
NCT02379585
Terminated
This study is to see how safe the use of short-term fasting is in breast cancer patients who will receive chemotherapy before undergoing surgery and to examine if the use of short-term fasting will decrease the side effects of chemotherapy and how much a tumor shrinks while receiving chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2018
Locations: Western Regional Medical Center, Goodyear, Arizona
Conditions: HER2-positive Breast Cancer
Register for Updates
Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation
NCT00626626
Terminated
Allogeneic hematopoietic transplant is curative for many patients with hematological neoplasms but conditions to provide optimal engraftment and anti-tumor efficacy with minimal toxicity are still under way. Clofarabine is a newly licensed agent with dramatic anti-leukemic activity. Its incorporation into a regimen for pre-transplant conditioning of acute leukemia and lymphoma patients is logical, exploiting both the anti-tumor activities it is recognized to have and the immunosuppressive activi... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/23/2018
Locations: Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
Register for Updates
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047
Completed
The purpose of this study is to find out if there is a benefit of adding Herceptin (trastuzumab) to standard chemotherapy in this type of breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/21/2018
Locations: Hays Medical Center, Hays, Kansas +1 locations
Conditions: Breast Cancer
Register for Updates
Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
NCT00004474
Completed
OBJECTIVES: I. Compare outcome, including graft failure, graft versus host disease, and survival of HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide with or without antithymocyte globulin as a conditioning regimen.
Gender:
ALL
Ages:
59 years and below
Trial Updated:
03/09/2018
Locations: Roswell Park Cancer Institute, Buffalo, New York +3 locations
Conditions: Aplastic Anemia
Register for Updates
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
NCT00256243
Completed
We proposed to use 4 cycles of AC q 2 weeks, as used in the dose dense adjuvant study with GM-CSF support on days 3-9 of the cycle. After the completion of AC we plan to administer paclitaxel and carboplatin weekly for a total of 12 doses with one week rest after every 3 weeks of treatment over 12 weeks. Patients who are her-2 over-expressors by FISH (fluorescence in situ hybridization) will also receive Trastuzumab with weekly carboplatin and paclitaxel as the combination TC±H has been found to... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/28/2018
Locations: Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Breast Cancer
Register for Updates
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
NCT00852709
Terminated
This is a Phase I study designed to determine the MTD and assess the toxicity associated with clofarabine followed by fractionated cyclophosphamide in patients \> 1 year of age or \< 21 years of age with relapsed or refractory acute leukemias. There will be 25 to 35 patients enrolled. Cohorts of 3 to 6 patients each will receive escalated doses of clofarabine followed by fractionated cyclophosphamide until the MTD is reached. There will be no intra-patient dose escalation. Single-agent cyclophos... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
02/13/2018
Locations: Phoenix Children's Hospital, Phoenix, Arizona +6 locations
Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia, Acute Promyelocytic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia
Register for Updates
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
NCT00194779
Completed
This phase II trial studies how well giving combination chemotherapy and filgrastim together before surgery works in treating patients with human epidermal growth receptor 2 (HER2)-positive breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy before surgery... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/12/2018
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Register for Updates
Tecemotide (L-BLP25) in Prostate Cancer
NCT01496131
Completed
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/09/2018
Locations: Please Contact US Medical Information, Rockland, Massachusetts
Conditions: Prostate Cancer
Register for Updates